Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease

Completed

Conditions studied: Lung Diseases, Interstitial

In brief

The purpose of this study is to describe initiation and use of oxygen therapy among patients with fibrotic Interstitial Lung Disease (ILD) and to assess the impact of oxygen therapy on clinical outcomes among patients with fibrotic ILD.

Key facts

Study ID

NCT05957198

Run by

Boehringer Ingelheim

People needed

114921

Starts

2023-07-25

Expected to finish

2023-09-26

Last updated by the study team

2024-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥2 fibrosing Interstitial Lung Disease (ILD) diagnoses in any position on different dates of service, within 365 days of each other, and in the same continuous enrollment period during the patient identification period. The fibrosing ILD diagnosis date will be defined as the date of the first fibrosing ILD diagnosis. The two fibrosing ILD diagnosis codes can be one of the following combinations:
• 2 fibrosis codes
• 1 fibrosis code \& 1 ILD code that requires fibrosis code
• ≥18 years of age as of the fibrosing ILD diagnosis date
• Continuous enrollment with medical and pharmacy coverage for 12 months prior to the fibrosing ILD diagnosis date (pre-ILD baseline period)

You may not qualify if…

• Fibrosing ILD diagnosis in the 12-month pre-ILD baseline period
• Unknown gender, geographic region, or insurance type

Where it is running

• Boehringer Ingelheim Pharmaceuticals, Inc. — Ridgefield, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.